Cardio-oncology study

Detecting and treating subclinical anthracycline therapy related cardiac dysfunction in low income country

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

PACTR

Registry ID

PACTR201804003218439

Enrollment

Registered

2018-03-19

Start date

2018-04-19

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Circulatory System Anthracycline therapy related cardiac dysfunction Cardiology

Interventions

Carvedilol

No intervention

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: age: 18 to 50 years Cancer patients who received anthracycline therapy and developed subclinical ATRCD during follow up

Exclusion criteria

Exclusion criteria: Patient who is taking carvedilol Patient who has any of the conditions:HT,DM,CKD,CAD Patient who has low LVEF

Design outcomes

Primary

Measure	Time frame
Prevention of the worsening of GLS(global longitudinal strain)	—

Secondary

Measure	Time frame
Reduce the level of oxidative stress	—

Countries

Uganda

Contacts

Public ContactKaren Sliwa

Director, Hatter Institute for Cardiovascular Research in Africa,

karen.sliwa-hahnle@uct.ac.za+27 21 021 406 6457

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Aug 9, 2026